Nektar Therapeutics Q1 FY2026 earnings call

Key managerial messages include details on atopic dermatitis program maintenance dosing after induction, durability of responses in RESOLVE-AD study, bioexperience patient study definition for atopic dermatitis, thoughts on regulatory approval for trials, details on 1665 program, alopecia areata program treatment period and phase three considerations, and points to hammer out with FDA after end of phase two meeting such as phase three trial number, study design powering and eligibility criteria, and safety data alignment

Not applicable as no specific product segment financial performance data provided

Look forward to initiating phase three studies in atopic dermatitis in the coming months, advancing alopecia areata into phase three, and exploring other respec potential in T-cell mediated diseases

Not discussed in detail in the provided transcript

Q: On bioexperience patient study in atopic dermatitis, how defined; A: Candidates require systemic therapy, history of atopic dermatitis for at least 12 months, inadequate response to topical meds, and either biologic or JAK inhibitor; Q: Need to be successful in all three trials for approval; A: Believed showing efficacy in two well-controlled randomized trials could be sufficient for regulatory approval but will have conversations with FDA; Q: On AD off-therapy durability data and 1665 program; A: Discussed EZ100 evolution, 166 program details like bispecific nature and IND enabling studies; Q: On alopecia areata program 24-week treatment period and phase three inclusion; A: Chose 24-week off-treatment due to JAK inhibitor hair loss, phase three with JAK inhibitor naive patients but will explore JAK inhibitor experienced; Q: On phase three in alopecia and FDA pushback; A: Best path forward with SALT 50 or above population, no pushback received yet but will have conversation; Q: On phase three in alopecia and points to hammer out with FDA; A: Important points include phase three trial number precedence, study design powering and eligibility criteria, and safety data alignment